These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 15991103)

  • 1. Patient preferences and cost-utility analysis.
    Elnitsky CA; Stone P
    Appl Nurs Res; 2005 May; 18(2):74-6. PubMed ID: 15991103
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [QALYS or not QALYS: that is the question?].
    Moatti JP; Auquier P; Le Coroller AG; Macquart-Moulin G
    Rev Epidemiol Sante Publique; 1995 Dec; 43(6):573-83. PubMed ID: 8552855
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new and more robust test of QALYs.
    Doctor JN; Bleichrodt H; Miyamoto J; Temkin NR; Dikmen S
    J Health Econ; 2004 Mar; 23(2):353-67. PubMed ID: 15019761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-utility analysis in schizophrenia.
    Awad AG; Voruganti LP
    J Clin Psychiatry; 1999; 60 Suppl 3():22-6; discussion 27-8. PubMed ID: 10073373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advantages and limitations of utility assessment methods in rheumatoid arthritis.
    Beresniak A; Russell AS; Haraoui B; Bessette L; Bombardier C; Duru G
    J Rheumatol; 2007 Nov; 34(11):2193-200. PubMed ID: 17937471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Live long, live well: quantifying the health of heterogeneous populations.
    Mullahy J
    Health Econ; 2001 Jul; 10(5):429-40. PubMed ID: 11466804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preference-based quality of life measures in people with visual impairment.
    Kymes SM; Lee BS
    Optom Vis Sci; 2007 Aug; 84(8):809-16. PubMed ID: 17700344
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Community or patient preferences for cost-effectiveness of cardiac rehabilitation: does it matter?
    Oldridge N; Furlong W; Perkins A; Feeny D; Torrance GW
    Eur J Cardiovasc Prev Rehabil; 2008 Oct; 15(5):608-15. PubMed ID: 18800005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tamoxifen for breast cancer risk reduction: impact of alternative approaches to quality-of-life adjustment on cost-effectiveness analysis.
    Melnikow J; Birch S; Slee C; McCarthy TJ; Helms LJ; Kuppermann M
    Med Care; 2008 Sep; 46(9):946-53. PubMed ID: 18725849
    [TBL] [Abstract][Full Text] [Related]  

  • 10. What do utilities measure?
    Tsevat J
    Med Care; 2000 Sep; 38(9 Suppl):II160-4. PubMed ID: 10982102
    [No Abstract]   [Full Text] [Related]  

  • 11. Deriving welfare measures from discrete choice experiments: inconsistency between current methods and random utility and welfare theory.
    Lancsar E; Savage E
    Health Econ; 2004 Sep; 13(9):901-7. PubMed ID: 15362181
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Measures of burden of disease--new indicators of the health situation].
    Wvsocki MJ; Sakowska I; Car J
    Przegl Epidemiol; 2005; 59(1):125-34. PubMed ID: 16013418
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Longevity bias in cost-effectiveness analysis.
    Liu L; Rettenmaier AJ; Saving TR
    Health Econ; 2008 Apr; 17(4):523-34. PubMed ID: 17990284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deriving welfare measures in discrete choice experiments: a comment to Lancsar and Savage (1).
    Ryan M
    Health Econ; 2004 Sep; 13(9):909-12; discussion 919-24. PubMed ID: 15362182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjusting to changes in health: implications for cost-effectiveness analysis.
    Sharma R; Stano M; Haas M
    J Health Econ; 2004 Mar; 23(2):335-51. PubMed ID: 15019760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-utility analysis of cochlear implants in Korea using different measures of utility.
    Lee HY; Park EC; Kim HJ; Choi JY; Kim HN
    Acta Otolaryngol; 2006 Aug; 126(8):817-23. PubMed ID: 16846923
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterizing preferences for health outcomes in economic evaluations.
    Tosteson AN
    J Rheumatol Suppl; 2003 Dec; 68():15-8. PubMed ID: 14725249
    [No Abstract]   [Full Text] [Related]  

  • 18. Cost-utility of treatment of bulimia nervosa.
    Pohjolainen V; Räsänen P; Roine RP; Sintonen H; Wahlbeck K; Karlsson H
    Int J Eat Disord; 2010 Nov; 43(7):596-602. PubMed ID: 19806609
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utility measures of health-related quality of life in patients treated for benign paroxysmal positional vertigo.
    Roberts RA; Abrams H; Sembach MK; Lister JJ; Gans RE; Chisolm TH
    Ear Hear; 2009 Jun; 30(3):369-76. PubMed ID: 19322083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A value-based medicine analysis of ranibizumab for the treatment of subfoveal neovascular macular degeneration.
    Brown MM; Brown GC; Brown HC; Peet J
    Ophthalmology; 2008 Jun; 115(6):1039-1045.e5. PubMed ID: 17976724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.